G-CSF therapy in JAGN1-deficient patients with or without syndromic features. The plot shows the details of G-CSF treatment in the study cohort. Patients with syndromic features needed significantly higher doses of G-CSF than those without. In the group with syndromic features, 75% of the patients received 10 to 40 μg of G-CSF, whereas in the group without syndromic features, only 25% received high doses of 10 to 40 μg of G-CSF (P = .027).